Inspirna raises $50 million in Series D financing

New-York, USA-based Inspirna, a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, has raised $50 million in a Series D financing round, co-led by new investors Sands Capital and Vivo Capital, with additional participation from new investor Dreavent 6.

Proceeds from the financing will support the clinical development of Inspirna’s lead drug candidate RGX-202-01 (RGX-202), a first-in-class oral small molecule inhibitor of SLC6a8 to treat RAS mutant advanced colorectal cancer (CRC), and RGX-104, an oral small molecule activator of LXR/APOE to treat lung cancer and endometrial cancer.

The financing will provide the company with the funds necessary to further evaluate efficacy and safety for RGX-202 in second-line RAS mutant CRC in an ongoing Phase Ib clinical trial, for which the company recently disclosed interim data in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.